Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This case report underlines the importance of considering alternative diagnoses like ovarian steroid cell tumors in adolescent females with PCOS-like symptoms when standard treatments fail, highlighting the need for thorough evaluation and early intervention.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

This study found that dracorhodin perchlorate improved wound healing in diabetic rats by regulating the TLR4 pathway and related inflammatory factors.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

In this animal study, petroleum ether and ethanolic extracts of Abrus precatorius seeds appeared to reverse androgen-induced alopecia in male albino rats by inhibiting the 5α-reductase enzyme, similar to finasteride.

In this narrative review, the authors highlighted that AI-supported electronic health record analysis could help recognize Polycystic Ovary Syndrome/Polyendocrine Metabolic Ovarian Syndrome earlier, but also warned that these systems might perpetuate historical biases if not properly validated and interpreted.

This study found that both intralesional PRP and corticosteroids are effective for alopecia areata, but PRP offers higher patient satisfaction and fewer side effects, despite a slower initial response.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This study found that in a mouse model of PCOS, high androgen levels caused pyroptosis in ovarian granulosa cells and increased ER stress in oocytes, reducing oocyte maturation rates, while treatment with CPA and DMF improved these rates.

This study used theoretical calculations to show that phosphates strongly bind to cerium dioxide surfaces in various stable configurations, with spectral signatures identifiable in the infrared and Raman spectra, informing future experimental efforts in controlling the enzymatic activity of ceria nanoparticles.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study presents an improved protocol for isolating and culturing whole neonatal cochlear explants, enabling detailed analysis of hair cells and spiral ganglion neuron cells while simplifying culture steps without sacrificing explant quality, and was successfully tested on mice and rat cochleas.

This study developed and tested continuous implanters for dermal papilla cell aggregates, finding that the bar-cartridge type implanter is the most effective design for continuous cell implantation in androgenetic alopecia research.

This study suggests that 150 kHz electromagnetic radiation exposure may reduce follicular cysts and increase developing follicles in a rat model of polycystic ovaries without affecting hormonal levels or overall ovary morphology.

This study found that parenteral administration of cyproterone acetate was more effective than high-dose oral treatment in reducing facial hair diameter and improving dermatological parameters in patients with severe hirsutism, despite similar androgen suppression.

This study highlights that including scalp dermoscopy in diagnosing patients treated with the Regenera® protocol revealed that expected outcomes were often overestimated for those with poor prognosis.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

In this study, cedrol was found to reduce lipid accumulation in the liver and adipose tissues of dexamethasone-treated mice by antagonizing glucocorticoid receptors, suggesting its potential utility in treating dexamethasone-induced lipid metabolism disorders.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

This abstract pertains to a dermatology-related academic profile without reporting any specific study findings. Results or research details are not provided.

This study found that clippers are the safest and most efficient tool for collecting hair samples from companion dogs, with no impact on cortisol concentration compared to scissors.

This study developed a transgenic mouse model to explore androgenetic alopecia, finding that inducible COX2 expression led to sebaceous gland changes and hair miniaturization, with reversible effects upon reducing COX2.

This study presents the G4 transgenic mouse model, which suggests a direct link between polycystic ovary syndrome and the Gm10800 gene, offering a valuable tool for understanding the disease and testing treatments.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.